Common Language For Regulatory Harmonization Takes Shape In Asia, But Mutual Recognition Unlikely Anytime Soon
This article was originally published in PharmAsia News
Executive Summary
Regulators, industry and health care agencies are increasingly using the same language to describe efforts at harmonization for drug approvals and manufacturing. But even though mutual recognition agreements on drug approvals are the “ultimate goal,” getting there in Asia could take a decade or more.
You may also be interested in...
Voices From Emerging Markets Expected At Next ICH Steering Committee - APEC Harmonization Center Regulatory Conference
SEOUL - When ICH was created in 1990, Japan, U.S. and EU were the only participants, but more and more regulatory agencies are adopting variations of ICH guidelines for their own countries. In June, ICH's technical working groups will for the first time be expanded to include regional harmonization initiatives (RHIs), which regulators are calling a "dramatic change" towards global harmonization
Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections (Part 1)
As Asian drug regulatory authorities gain confidence in their ability to regulate new drug products, they are subjecting applicants to increasingly extensive chemistry, manufacturing and controls reviews, more like those of first-tier authorities in the U.S. and Europe
ASEAN Makes Slow But Steady Progress Toward Harmonization Of Pharmaceutical Regulations
SHANGHAI - The Association of Southeast Asian Nations is slated to implement common technical documents starting this year as part of "harmonized" pharmaceutical regulations in the region, which could benefit consumers by 2010